Zoetis (ZTS) Cash from Investing Activities (2012 - 2026)
Zoetis' (ZTS) quarterly Cash from Investing Activities came in at -$300.0 million in Q2 2026, down 41.51% year-over-year from -$512.9 million in Q2 2025, and down 244.83% quarter-over-quarter from -$87.0 million in Q1 2026.
Analysis
Zoetis (ZTS) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Cash from Investing Activities for 15 consecutive years, with -$300.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities fell 41.51% year-over-year to -$300.0 million in Q2 2026; TTM through Jun 2026 was -$720.0 million, a 54.18% decrease from a year earlier, with the FY2025 full-year figure at -$748.0 million, down 137.46% from the prior year.
- Cash from Investing Activities was -$300.0 million for Q2 2026 at Zoetis, down from -$87.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $126.0 million in Q4 2024 and troughed at -$438.0 million in Q4 2022.
- A 5-year average of -$172.8 million and a median of -$172.5 million in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities surged 160.0% in 2024 and slumped 231.75% in 2025, its largest moves.
- Over 5 years, Cash from Investing Activities stood at -$438.0 million in 2022, then jumped by 52.05% to -$210.0 million in 2023, then surged by 160.0% to $126.0 million in 2024, then tumbled by 231.75% to -$166.0 million in 2025, then sank by 80.72% to -$300.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$300.0 million (Q2 2026), -$87.0 million (Q1 2026), and -$166.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | -25.50 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | -300.00 Mn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | -110.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | -16.45 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | -55,116.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -300.00 Mn |
| Mar 31, 2026 | -87.00 Mn |
| Dec 31, 2025 | -166.00 Mn |
| Sep 30, 2025 | -167.00 Mn |
| Jun 30, 2025 | -212.00 Mn |
| Mar 31, 2025 | -203.00 Mn |
| Dec 31, 2024 | 126.00 Mn |
| Sep 30, 2024 | -178.00 Mn |
| Jun 30, 2024 | -132.00 Mn |
| Mar 31, 2024 | -131.00 Mn |
| Dec 31, 2023 | -210.00 Mn |
| Sep 30, 2023 | -271.00 Mn |
| Jun 30, 2023 | -80.00 Mn |
| Mar 31, 2023 | -216.00 Mn |
| Dec 31, 2022 | -438.00 Mn |
| Sep 30, 2022 | -124.00 Mn |
| Jun 30, 2022 | -203.00 Mn |
| Mar 31, 2022 | -118.00 Mn |
| Dec 31, 2021 | -142.00 Mn |
| Sep 30, 2021 | -114.00 Mn |